Learn the CFO/EBITDA cash-conversion ratio — the 60-second test that separates real operating profits from accounting fiction — using Titan Biotech FY25's 103% audited reading as a positive illustration.

Ellen Langer's 1975 illusion-of-control experiments explain why 91.1% of Indian F&O traders lose money — and the 8-point counter-measure checklist serious long-term investors must install. Titan Biotech FY25's ₹3 Cr borrowings, 103% CFO/Operating Profit, and 36.4% independent-board ratio illustrate the corporate analogue of the anti-bias discipline (educational case study, not a valuation call).

A long-form educational deep-dive on Other Income as a percentage of Profit Before Tax — the 30-second forensic earnings-quality filter that separates real Indian operating businesses from non-operating bookkeepers. Illustrated using Titan Biotech FY25 audited disclosures (operating-led ~₹214 Cr revenue, ~18-22% EBITDA margin, CFO/Operating Profit at ~103%, total borrowings ₹3 Cr) as a positive educational example. Educational content only — not a buy/sell recommendation.